PMID: 11604359Oct 18, 2001Paper

Dose intensity of chemotherapy in small-cell lung carcinoma

Bulletin du cancer
C BorgV Trillet-Lenoir

Abstract

Small cell lung cancer accounts for 20% of the primitive lung carcinomas. The pronostic is unfavourable, since two thirds of the patients present with extensive stage at diagnosis. The median survival without treatment is less than 3 months. Chemotherapy is the standard front line therapy. In selected patients, chest irradiation and so-called prophylactic cerebral irradiation are current options. Small cell lung cancer is a chemosensitive disease. Indeed, the response rate is around 80-95% of in limited disease patients of which 50-60% are complete responses. Despite these results, the median survival does not exceed 16 months. Early recurrences after initial response probably reflect various resistances mechanisms. Furthermore, small cell lung cancer is associated with a high fraction of dividing cells. It is a clinical model where the dose-response relationship concept is worth testing, and dose-intensity may be integrated into the therapeutic strategies. Therefore, many clinical trials have assessed these principles during the past 20 years. We present here the different methods of therapeutic intensification in small cell lung cancer: with or without hematopoïetic supports, using initial high dose of cytotoxic drugs, either...Continue Reading

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Revue des maladies respiratoires
R de CrevoisierT Le Chevalier
Annals of Oncology : Official Journal of the European Society for Medical Oncology
S Zöchbauer-MüllerH Huber
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
P J WollR Pettengell
Annals of Oncology : Official Journal of the European Society for Medical Oncology
A Le CesneR Arriagada
© 2021 Meta ULC. All rights reserved